Based on a board resolution dated May 12, 2026, we conducted a share buyback of common stock. From June 1 to June 30, 2026, the cumulative number of shares acquired through market purchases was 1,244,100 shares, with a total acquisition value of 2,604,697,050 yen. The cap is 13,000,000 shares and 150,000,000,000 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4272","jir_company_name":"\u65e5\u672c\u5316\u836f\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4272-20260706-01.pdf","jir_short_summary":"Based on a board resolution dated May 12, 2026, we conducted a share buyback of common stock. From June 1 to June 30, 2026, the cumulative number of shares acquired through market purchases was 1,244,100 shares, with a total acquisition value of 2,604,697,050 yen. The cap is 13,000,000 shares and 150,000,000,000 yen.","jir_summary":"### Section Heading\nNihon Kagaku Pharmaceutical Co., Ltd. continues to disclose share buybacks with the aim of enhancing shareholder value. From June 1 to June 30, 2026, we acquired 1,244,100 shares of common stock through market purchases, with a total acquisition value of approximately 260 million yen. In the prior resolution, the cap was set at 13,000,000 shares and 15,000,000,000 yen, with the acquisition period planned from May 13, 2026, to March 31, 2027. Acquisition is contemplated with consideration for the total number of issued shares.\n\n### Section 2 heading\nThis acquisition is conducted through market purchases, and cumulative progress toward the cap remains within room. Further acquisitions will be considered depending on the policy and market conditions. The purpose is to improve capital efficiency and strengthen shareholder returns, with execution anticipated at an appropriate timing and scale.","jir_financial_highlights":"Total number of shares acquired: 1,244,100 shares (Cumulative within period)\nTotal acquisition value: 2,604,697,050 yen (Cumulative amount acquired)\nAcquisition period (actual): 2026\/6\/1\uff5e2026\/6\/30 (Execution-based)\nAcquisition period (board-approved limit): 2026\/5\/13\uff5e2027\/3\/31 (Limit period)","jir_category":"","jir_hashtags":"#NihonKagakuPharmaceutical, #ShareBuyback, #JapaneseStocks","jir_key_figures":"Total number of shares acquired: 1,244,100 shares\nTotal acquisition value: 2,604,697,050 yen\nMaximum number of shares for acquisition: 13,000,000 shares (limit)","jir_meta_title":"Nihon Kagaku Pharmaceutical \u2014 Notice on Share Buyback Status | June 2026 Results","jir_meta_description":"Nihon Kagaku Pharmaceutical is conducting a share buyback. For June 2026, the number of shares acquired is 1,244,100 and the total acquisition value is 2,604,697,050 yen. The board-approved limit is 13,000,000 shares and 15 trillion yen. Future acquisition policy is noted.","jir_og_title":"Nihon Kagaku Pharmaceutical \u2014 Notice on Share Buyback Status","jir_og_description":"Nihon Kagaku Pharmaceutical announced that the cumulative share buyback as of June 2026 was 1,244,100 shares, with a total value of about 260 million yen. The cap is 13,000,000 shares, with a period from 2026\/5\/13 to 2027\/3\/31.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8762,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-76473","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n